Emergent BioSolutions Framtida tillväxt
Future kriterier kontrolleras 1/6
Emergent BioSolutions förväntas öka vinsten och intäkterna med 120.7% och 15.5% per år respektive medan EPS förväntas växa med 120.5% per år.
Viktig information
120.7%
Tillväxttakt i vinsten
120.51%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.3% |
| Intäkternas tillväxttakt | 15.5% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 04 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Apr 22
EBS: Earnings Reset And Buybacks Will Support Long Term Contract Upside
Narrative Update The consensus analyst price target for Emergent BioSolutions has been cut by $3 to $12. Analysts cite reduced earnings expectations after the recent earnings miss as the key driver of this change.Uppdatering av berättelse • Apr 07
EBS: Earnings Reset And Buybacks Will Support Smallpox Contract Upside Potential
Analysts have trimmed their price target for Emergent BioSolutions to $12 from $15, citing reduced earnings expectations following the recent earnings miss. Analyst Commentary Bullish Takeaways Bullish analysts are keeping a positive stance on the shares even after the earnings miss, suggesting they still see room for upside from the current price level.Uppdatering av berättelse • Mar 24
EBS: Earnings Reset And Buybacks Will Support Future Upside Potential
Analysts have trimmed their price target on Emergent BioSolutions to $12 from $15, citing lowered earnings expectations following the recent earnings miss. Analyst Commentary Analysts have reacted to the earnings miss by cutting their price target on Emergent BioSolutions to $12 from $15, reflecting reduced earnings expectations while still seeing room for potential upside at current levels.Uppdatering av berättelse • Mar 09
EBS: Reset Earnings Bar And Buybacks Will Support Future Upside
Analysts have reduced their fair value estimate for Emergent BioSolutions to $12 from $13.50, citing lower earnings expectations after the recent miss, while also updating their assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts are still comfortable assigning a fair value of $12, which suggests they see the earnings miss as an adjustment to expectations rather than a thesis-breaking event.Analysartikel • Dec 23
Emergent BioSolutions Inc. (NYSE:EBS) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Emergent BioSolutions Inc. ( NYSE:EBS ) shares have been powering on, with a gain of 28...Analysartikel • Nov 27
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Nov 07
Emergent BioSolutions: Solid Q3, Expecting Better Days To Come
Summary Emergent BioSolutions maintains a Buy rating, supported by recent Q3 earnings beat and CEO Joe Papa's turnaround progress. EBS reported Q3 revenues of $231.1M and net income of $51.2M, surpassing guidance, with improved capital allocation and reduced net debt. Narcan sales declined year-over-year due to pricing and volume pressures, but sequential growth and strong demand signal market stabilization. Cost reductions, strategic government contracts, and effective downsizing position EBS for improved performance and potential upside amid sector challenges. Read the full article on Seeking AlphaAnalysartikel • Oct 08
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry
The Emergent BioSolutions Inc. ( NYSE:EBS ) share price has done very well over the last month, posting an excellent...Analysartikel • Aug 24
Improved Revenues Required Before Emergent BioSolutions Inc. (NYSE:EBS) Stock's 29% Jump Looks Justified
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 29% gain in the last month...Analysartikel • Aug 15
Emergent BioSolutions' (NYSE:EBS) Solid Earnings May Rest On Weak Foundations
NYSE:EBS 1 Year Share Price vs Fair Value Explore Emergent BioSolutions's Fair Values from the Community and select...Analysartikel • Aug 10
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50
The investors in Emergent BioSolutions Inc. 's ( NYSE:EBS ) will be rubbing their hands together with glee today, after...Analysartikel • Jul 05
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • May 11
Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Those holding Emergent BioSolutions Inc. ( NYSE:EBS ) shares would be relieved that the share price has rebounded 29...
Ny berättelse • Apr 26
Transformational Initiatives Will Optimize Medical Countermeasures And Operations
Strategic refocus on medical countermeasures and NARCAN Nasal Spray aims to maintain market leadership and drive revenue growth.Seeking Alpha • Mar 26
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Summary Emergent BioSolutions faces declining revenues, increasing competition, and limited growth potential, leading to a sell rating due to poor risk-reward profile. NARCAN, their main revenue generator, is experiencing pricing pressure and competition, with limited growth prospects outside North America. Management's plans for international expansion and future growth are vague and unlikely to succeed, further weakening the investment thesis. The company's financials show inconsistent revenue, declining profit margins, and reliance on asset sales, with no clear turnaround plan in sight. Read the full article on Seeking AlphaAnalysartikel • Mar 21
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet
The Emergent BioSolutions Inc. ( NYSE:EBS ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Mar 20
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues
Summary Emergent BioSolutions has faced significant challenges, with its stock price falling sharply since my previous article in July 2024. The company's updated mission focuses on combating health threats like smallpox, Ebola, anthrax, and opioid overdoses. I will evaluate Emergent's investment potential using Q4 2024 earnings reports, including its press release, conference call, 10-Q, and slides. This analysis aims to determine if Emergent's strategic goals align with its current financial performance and future prospects. Read the full article on Seeking AlphaAnalysartikel • Mar 05
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jan 22
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise
Emergent BioSolutions Inc. ( NYSE:EBS ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Jan 14
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Summary Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock. Read the full article on Seeking AlphaAnalysartikel • Nov 09
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 32% gain in the last month...Seeking Alpha • Nov 08
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Summary Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats. The significant share price increase underscores market optimism about Emergent's strategic direction and financial performance. The presence of veteran Joe Papa as CEO is a reassuring one - his ability to complete business transformations is impressive. If the CEO stays, EBS stock price is likely to keep growing. Read the full article on Seeking AlphaAnalysartikel • Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Oct 04
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Summary Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, the company raised its full-year revenue forecast and is focusing on improving operational efficiency and reducing debt. Emergent's involvement in global health crises, like mpox, and securing FDA approvals and contracts, positions it as a key player in biodefense. Risks remain due to reliance on government contracts and ongoing restructuring, but recent positive developments support a cautiously optimistic outlook for long-term growth. Read the full article on Seeking AlphaAnalysartikel • Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Aug 18
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Summary Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS’s stock rally is likely driven by its smallpox vaccine, ACAM2000, which has potential implications for monkeypox. Potential refinancing and strategic turnaround efforts mitigate the company's financial challenges, including significant debt and cash burn. EBS's MCM portfolio and new government contracts strengthen its position as a trusted biodefense partner. My speculative "buy" rating hinges on EBS’s ability to execute its turnaround, with added potential upside from its possible monkeypox vaccine approval. Read the full article on Seeking AlphaAnalysartikel • Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 41% gain in the last month...Seeking Alpha • Jul 15
Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process
Summary Emergent BioSolutions is a commercial stage company focused on developing vaccines and therapeutics to protect against public health threats worldwide. The company experienced a steep decline in stock value due to manufacturing mishaps and scandal during the pandemic, but is now recovering under new CEO Joseph Papa. Despite recent revenue stabilization and positive prospects, investors should approach Emergent with caution. Read the full article on Seeking AlphaPrognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2027 | 892 | 48 | N/A | N/A | 1 |
| 12/31/2026 | 733 | -16 | N/A | N/A | 2 |
| 3/31/2026 | 677 | -9 | 155 | 148 | N/A |
| 12/31/2025 | 743 | 53 | 207 | 171 | N/A |
| 9/30/2025 | 789 | 76 | 81 | 13 | N/A |
| 6/30/2025 | 852 | 140 | 235 | 169 | N/A |
| 3/31/2025 | 965 | -132 | 154 | 110 | N/A |
| 12/31/2024 | 1,044 | -191 | 66 | 59 | N/A |
| 9/30/2024 | 1,126 | -209 | 138 | 171 | N/A |
| 6/30/2024 | 1,102 | -587 | 31 | 77 | N/A |
| 3/31/2024 | 1,185 | -565 | -138 | -85 | N/A |
| 12/31/2023 | 1,049 | -760 | -264 | -206 | N/A |
| 9/30/2023 | 1,103 | -778 | -216 | -146 | N/A |
| 6/30/2023 | 1,072 | -602 | -602 | -280 | N/A |
| 3/31/2023 | 974 | -394 | -523 | -181 | N/A |
| 12/31/2022 | 1,118 | -212 | -394 | -34 | N/A |
| 9/30/2022 | 1,491 | 33 | -180 | 201 | N/A |
| 6/30/2022 | 1,581 | 88 | 127 | 292 | N/A |
| 3/31/2022 | 1,757 | 158 | 78 | 279 | N/A |
| 12/31/2021 | 1,774 | 220 | 96 | 320 | N/A |
| 9/30/2021 | 1,653 | 227 | 23 | 237 | N/A |
| 6/30/2021 | 1,709 | 299 | 121 | 326 | N/A |
| 3/31/2021 | 1,706 | 387 | 300 | 483 | N/A |
| 12/31/2020 | 1,577 | 306 | 385 | 537 | N/A |
| 9/30/2020 | 1,333 | 167 | 262 | 413 | N/A |
| 6/30/2020 | 1,259 | 170 | 184 | 305 | N/A |
| 3/31/2020 | 1,108 | 68 | 41 | 141 | N/A |
| 12/31/2019 | 1,106 | 55 | N/A | 188 | N/A |
| 9/30/2019 | 1,016 | 4 | N/A | -100 | N/A |
| 6/30/2019 | 878 | -18 | N/A | 77 | N/A |
| 3/31/2019 | 855 | 42 | N/A | 148 | N/A |
| 12/31/2018 | 782 | 63 | N/A | 42 | N/A |
| 9/30/2018 | 706 | 100 | N/A | 285 | N/A |
| 6/30/2018 | 681 | 113 | N/A | 146 | N/A |
| 3/31/2018 | 562 | 67 | N/A | 165 | N/A |
| 12/31/2017 | 561 | 83 | N/A | 208 | N/A |
| 9/30/2017 | 519 | 81 | N/A | 118 | N/A |
| 6/30/2017 | 512 | 68 | N/A | 110 | N/A |
| 3/31/2017 | 503 | 61 | N/A | 54 | N/A |
| 12/31/2016 | 489 | 63 | N/A | 55 | N/A |
| 9/30/2016 | 497 | 73 | N/A | 70 | N/A |
| 6/30/2016 | 512 | 94 | N/A | 148 | N/A |
| 3/31/2016 | 529 | 125 | N/A | 153 | N/A |
| 12/31/2015 | 489 | 91 | N/A | 43 | N/A |
| 9/30/2015 | 478 | 79 | N/A | 93 | N/A |
| 6/30/2015 | 457 | 59 | N/A | 67 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: EBS förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: EBS förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: EBS förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: EBS s intäkter ( 15.5% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).
Hög tillväxtintäkter: EBS s intäkter ( 15.5% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om EBS s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/14 20:33 |
| Aktiekurs vid dagens slut | 2026/05/14 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Emergent BioSolutions Inc. bevakas av 15 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| James Molloy | Brean Capital Historical (Janney Montgomery) |